The macrophage migration inhibitory factor (MIF) is an intracellular inhibitor of the central nervous system actions of angiotensin II on blood pressure. Considering that angiotensin II actions at the nucleus of the solitary tract are important for the maintenance of hypertension in spontaneously hypertensive rats (SHRs), we tested if increased MIF expression in the nucleus of the solitary tract of SHR alters the baseline high blood pressure in these rats.
Introduction
The nucleus of the solitary tract (NTS), located in the dorsal brainstem, is the first synaptic relay station in the central nervous system (CNS) for cardiovascular afferent fibres. 1 -3 In fact, the NTS is more than a synaptic relay for cardiovascular afferents, since it plays a part in mediating the high blood pressure and sympathoexcitation seen in spontaneously hypertensive rats (SHRs). 4 -6 GABA injections or electrolytic lesions of the commissural NTS (commNTS), a caudal region of the NTS, were able to decrease blood pressure or reduce sympathetic activity in SHRs, but failed to change these parameters in normotensive (NT) rats.
Activity of the renin -angiotensin system (RAS) is also increased in SHRs in both central and peripheral tissues. 7 With respect to the CNS RAS, it has been reported that the level of angiotensin II (ANGII) type 1 (AT1) receptor mRNA is greater in the hypothalamus and the brainstem of SHRs compared with NT control rats. 8, 9 SHRs exhibit hyperactivity of the sympathetic nervous system and also an impairment in baroreflex function. 10 Collectively, these findings indicate that NTS hyperactivity, an increase in central RAS activity (including in the brainstem), increased sympathetic tone and a loss of baroreflex function could be involved in the development and/or maintenance of hypertension in SHRs.
In our efforts to understand how the actions of ANG II are normally offset in the brain, we demonstrated that the macrophage migration inhibitory factor (MIF) is an intracellular negative regulator of the AT1 receptor-mediated actions of this peptide. 11 Further, we demonstrated that the pressor and dipsogenic actions of intracerebroventricular ANG II are diminished in rats with an increased expression of MIF in the paraventricular nucleus of hypothalamus (PVN), 12 a brain region important for the control of sympathetic outflow, the hypothalamus-pituitary axis, and fluid-electrolytic balance. 13, 14 It is apparent that MIF elicits these inhibitory effects via its intrinsic thiolprotein oxidoreductase (TPOR) activity, 15 with subsequent scavenging reactive oxygen species (ROS),which are a critical element of AT1 receptor-coupled intracellular signalling in the CNS. 16 Transient viral-mediated transduction of MIF into the PVN has been also demonstrated to reduce the sympathoexcitation induced by hyperosmolality, 17 an effect dependent on PVN AT1 receptors, 17, 18 and also to decrease the raised blood pressure in SHRs. 19 In fact in SHRs, MIF expression in PVN neurons is diminished compared with NT rats, and this can account for the reduction in the counter-regulatory effect of MIF over the central ANG II pressor effects. 19 In a recent study it was demonstrated that in SHRs, both ROS levels in the NTS (intermediate and commissural NTS subregions) and blood pressure are reduced after 2 weeks of treatment with losartan (AT1 receptor antagonist) or tempol (superoxide dismutase mimetic) applied to the drinking water. 20 Since the NTS is important for arterial blood pressure control, and has a role in hypertension, the aim of the current study was to investigate the effects of an increased expression of MIF in NTS neurons of SHRs on blood pressure, baroreflexes, and heart function.
The data indicate that an increased expression of MIF in NTS neurons improves baroreflex function and lowers blood pressure in SHRs.
Methods

Animals
Eight-week-old male SHRs and age-matched NT Wistar Kyoto rats ( 250 g) were obtained from Charles River Farms (Wilmington, MA, USA). Rats were kept on a 12-h light -dark cycle in a climate-controlled room. Food and water were provided ad libitum. All experimental procedures were approved by the Institutional Animal Care and Use Committees of the University of Florida and the Ethical Committee for Animal Care and Use from the Dentistry School of São Paulo State University. In addition, the principles governing the care and treatment of animals, as stated in the Guide for the Care and Use of Laboratory Animals published by the National Academy of Sciences (eighth ed., 2011), were followed at all times during this study.
Anaesthesia and euthanasia
The anaesthesia used in these studies depended upon the surgery or experimental protocol, as follows. For the surgeries to implant telemetry transducers or perform microinjections of viral vectors into the NTS, anaesthesia was induced using 100% O 2 /4% isoflurane, and was maintained throughout the surgeries by the administration of 100% O 2 /2% isoflurane. For the cardiac function experiments, rats were anaesthetized with a ketamine/xylazine/acepromazine cocktail (30 mg/6 mg/1 mg/kg, im), and for implantation of arterial and venous catheters for the baroreflex studies rats were anaesthetized via ip injection of ketamine [80 mg/kg body weight (bw)] combined with xylazine (7 mg/kg bw). During these surgeries/procedures, the level of anaesthesia was monitored by checking the eye blink reflex and a reaction to paw pinch, and was adjusted if necessary. Buprenorphine (0.05 mg/kg, sc) was administered to rats immediately following the survival surgeries (telemetry transducers, NTS microinjections and catheter implantation).
All rats were euthanized by placing them under deep anaesthesia with 100% O 2 /5% isoflurane, followed by either decapitation or transcardial perfusion with 0.9% saline containing 4% formaldehyde, depending on the protocol.
Experimental protocols
Rats were used in the following experimental protocols.
Experiment 1
(i) Fourteen-week-old NT rats and SHRs were placed under deep anaesthesia as above, euthanized by decapitation, brains removed and used for the analysis of MIF mRNA in the PVN. (ii) Fourteen-week-old NT rats and SHRs were placed under deep anaesthesia, perfused transcardially with formaldehyde, brains were removed and immunostaining performed to determine the cellular localization (neurons or astroglia) of endogenous immunoreactive MIF within the NTS. The age of the rats used in these experiments (14 weeks) was picked to match the approximate age the rats in Experiments 2 and 3 had reached at the termination of those experiments.
Experiment 2
Eight-week-old NT rats and SHRs were implanted with telemetry transducers into the abdominal aorta, and 10 days later rats received microinjections of either AAV2-CBA-eGFP or AAV2-CBA-MIF into the NTS. Recordings of the mean arterial blood pressure (MAP) and heart rate (HR) were made 3 days before, on the day of, and at 3, 6, 10, 14, 18, 21, 25, 28, and 31 days post-vector injection. MAP and HR were recorded continuously a 24-h period on each of these days. After the recordings on Day 31, rats were anaesthetized and their cardiac function was assessed. Immediately following this procedure rats were euthanized and either used for the analysis of cardiac hypertrophy or for the localization of GFP or immunoreactive MIF within the NTS.
Experiment 3
Eight-week-old NT rats and SHRs were microinjected with either AAV2-CBA-eGFP or AAV2-CBA-MIF into the NTS. Thirty days later, rats were anaesthetized and implanted with two catheters: one into the abdominal aorta through the femoral artery for direct recordings of MAP and HR, and another into the femoral vein for drug administration. The next day, in conscious rats, MAP and HR were recorded followed by the analysis of baroreflex function. Following these tests, rats were deeply anaesthetized, perfused transcardially with formaldehyde, and brains were removed to confirm the localization of GFP or immunoreactive MIF within the NTS.
Details of the experimental procedures (surgeries, injections, etc.) used in these protocols are as follows.
Telemetry recordings of MAP and HR
Anaesthesia was induced with isoflurane as above, and telemetry transducers (DSI, St Paul, MN, USA) were implanted into the abdominal aorta as detailed previously. 12 Chronic measurements of MAP and HR continued for 31 days (24 h recordings, twice/week) after gene transduction into the NTS.
In vivo gene transfer in the NTS
Ten days after the surgeries to implant telemetry transducers, rats were anaesthetized with isoflurane as above and placed in a stereotaxic frame (David Kopf Instuments, Tujunga, CA, USA). AAV2-CBA-eGFP or AAV2-CBA-MIF was constructed as described previously, and these vectors elicit gene transduction primarily in neurons of all different phenotypes. 19 Each of these vectors was microinjected at five different sites along the NTS [150 nL/site; 1 × 10 9 genome copies (gc)/injection] as follows: at the level of the calamus scripitorius and 0.5 mm rostral and 0.4 mm caudal to it; 0.2 -0.5 mm lateral from the midline and 0.4 mm ventral to the dorsal surface of the medulla. Each injection was made over a period of 1 min. Surgical procedures used for these microinjections were as detailed previously. 19 
Cardiac function and hypertrophy
Rats were anaesthetized with a ketamine/xylazine/acepromazine cocktail as described above, placed in a supine position and the body temperature was maintained at 378C using a heated pad. The left ventricular function was measured using a 22-Gauge needle filled with heparinized saline (20 IU/mL) inserted into the left ventricular chamber. Data were recorded after stabilization of the tracing using a liquid pressure transducer, which was interfaced to a PowerLab (ADInstruments, Colorado Springs, CO, USA) signal transduction unit. Data were analysed using the Chart program that was supplied with the PowerLab system. Maximal positive and negative rates of rise in the left ventricular pressure (+LVdP/dt max ) were analysed. At the end of the experiments, rats were euthanized as above, and cardiac hypertrophy was assessed by determining heart weight (HW)/tibial length (TL) ratios as described previously. 21 
Baroreflex function
On the day before the assessment of baroreflex function, rats were anaesthetized via ip injection of ketamine and xylazine as described above and a polyethylene tube (PE-10 connected to a PE-50) was inserted into the abdominal aorta through the femoral artery. Another PE-50 catheter was implanted into the femoral vein. Arterial and venous catheters were tunneled subcutaneously and exposed on the back of the rat to allow access to unrestrained, freely moving animals. The day following these surgeries baroreflex function was assessed in conscious rats. 
Immunohistochemistry
Animals were deeply anaesthetized with isoflurane as above and brains were perfused transcardially with 0.9% saline containing 4% formaldehyde. Brainstems were removed, frozen, and cut in 30 mm coronal sections on a cryostat (Leica, CM1800). Rat brainstem sections were pre-incubated for 15 min in a blocking solution composed of 10% (v/v) normal goat serum (NGS, Sigma, St Louis, MO, USA) and 0.3% (v/v) Triton X-100 (Sigma) in 0.1 mmol/L phosphate buffered saline (PBS) followed by rinses in PBS (3 × 10 min). Sections were then incubated with a polyclonal rabbit anti-MIF primary antibody (1:300 for intact animals or 1:500 for MIF-over expressed animals, Torrey Pines Biolabs, Inc., Houston, TX, USA) and mouse anti-HuC/HuD (1:5000, human neuronal-specific protein, Invitrogen, Carlsbad, CA, USA) or mouse anti-GFAP (1:500, Chemicon International, Temecula, CA, USA) in PBS containing 1% (v/v) NGS and 0.3% Triton X-100 for 24 h at 48C. Next, sections were rinsed in PBS (3 × 10 min) prior to 1-h incubation in Alexa Fluor 488 goat anti-rabbit and Alexa Fluor 594 goat anti-mouse (1:500, Molecular Probes). Following further rinses in PBS (3 × 5 min) sections were mounted onto slides in 0.5% gelatin and allowed to air-dry for 10-15 min before being cover slipped using antifade fluorescent mounting solution (VectorShield, Vector Laboratories, Burlingame, CA, USA). The sections were visualized using an Olympus BX-41 fluorescence microscope with the appropriate filter, in matched, representative sections of the tissue from different groups. No specific immunostaining was observed when the primary antibodies (MIF, HuC/HuD or GFAP) were omitted from the incubation.
qRT-PCR analyses
Rats were deeply anaesthetized with isoflurane as above, decapitated, brains removed and the NTS was removed by micropunch with the aid of a surgical microscope and using the obex as a reference site. MIF mRNA levels within the NTS were analysed by qRT-PCR as detailed by us previously, 19 and were expressed using the DDC T method normalized to 18S mRNA levels.
Data analysis
Data are expressed as means + SEM. Different statistical tests were applied for group comparisons depending on the experimental design. Student's t-test was used to compare mRNA levels and cardiac function data. One-way ANOVA was used for baroreflex function-and cardiac hypertrophy data, and two-way ANOVA was performed in blood pressure and HR measurements to compare treatments as a function of time. Both one-and two-way ANOVAs were followed by a Bonferroni post hoc test to compare individual means. In all tests, differences were considered significant at P , 0.05.
Results
Endogenous MIF mRNA levels and localization in the NTS of intact animals
qRT-PCR analyses as described in Experiment 1A in the Methods revealed that SHRs and NT rats displayed non-significantly different levels of MIF mRNA in the NTS (0.47 + 0.1 in SHRs vs. 0.62 + 0.13 in NT rats; values are in arbitrary units, from eight rats/group). However, our immunostaining experiments, as described in Experiment 1B in the Methods, suggest that there is a different cellular distribution of endogenous MIF in the NTS of the SHRs vs. the NT rats. The highpower representative fluorescence micrographs shown in Figure 1 suggest that in NT rats immunoreactive MIF is localized within neurons and to a lesser extent with astrocytes in the NTS, based on co-localization with HuC/HuD (neuron marker) and GFAP (astrocyte marker) respectively. However, the micrographs in Figure 1 also indicate that in SHRs the endogenous immunoreactive MIF is localized in astrocytes, but not in neurons. Based on our visualization of sections from this region of the NTS (214.2 mm from bregma) and also from all other regions of this nucleus, there was no association of immunoreactive MIF with neurons in the SHRs brain. Thus, from a qualitative perspective, there is a differential cellular distribution of immunoreactive MIF within the NTS of SHRs and NT rats.
Viral-mediated expression of GFP and MIF in the NTS
Considering the above findings, we wanted to determine whether the restoration of MIF within NTS neurons of SHRs would induce any cardiovascular alterations. We utilized AAV2-CBA-MIF and AAV2-CBAeGFP, which primarily induce the expression of MIF (and the control protein GFP) within neurons in the CNS. 19, 22 The representative fluorescence micrographs presented in Figure 2 (upper panels) show GFP (left) and MIF (right) at the level of the obex (214.28 mm from bregma), 31 days after microinjection of either AAV2-CBA-eGFP or AAV2-CBA-MIF into the NTS of SHRs, as described in Experiment 2 in the Methods. The higher power fluorescence micrographs presented in Figure 2 (lower panels) are from the NTS of SHRs at 31 days post-AAV2-CBA-MIF microinjection. These micrographs demonstrate that the MIF immunoreactivity produced by AAV2-CBA-MIF (staining was performed using more diluted MIF antibody that does not detect endogenous MIF) is localized primarily within neurons rather than astrocytes, based on co-localization with Huc/HuD and GFAP immunoreactivities, respectively. This pattern of MIF and GFP overexpression (in neurons as opposed to astrocytes) was similar following viral injections into NT rats. Of note, at the titers/volumes of viral vectors used in this study, there was no transfer of the vector to the forebrain (PVN) or other hindbrain (RVLM) cardiovascular control centres, and no consequent protein expression in these regions (not shown).
Increased expression of MIF in the NTS is associated with decreased mean arterial pressure in SHRs
The effects of increased MIF expression in the NTS on MAP and HR were examined as described in Experiment 2 in the Methods. Prior to viral transduction within the NTS, baseline MAP (mmHg) was similar between all SHR groups during light (eGFP: 132 + 2 and CBA-MIF: 134 + 3) and dark periods (eGFP: 135 + 2 and CBA-MIF: 133 + 3; Table 1 As shown in Figure 4 , baseline HR values, before vector transduction, were higher in the NT-MIF group compared with SHRs and the NT-eGFP group. Four weeks after vector transduction, HR levels were decreased only in the NT-MIF group compared with before MIF overexpression. 
MIF transduction in the NTS restores baroreflex function in SHRs
The effects of increased MIF expression in the NTS on baroreflex function were examined as described in Experiment 3 in the Methods. As demonstrated in Figure 5 , HR baroreflex function is Values are mean + SEM; n ¼ number of rats/group. *P , 0.05 vs. NT corresponding NT group. **P , 0.05 vs. NT + eGFP dark. expression of MIF in the NTS of NT rats did not alter the HR baroreflex function ( Figure 5 ).
No effect of MIF transduction in the NTS on cardiac function and hypertrophy of SHRs
The effects of an increased MIF expression in the NTS on cardiac function and hypertrophy were examined as described in Experiment 2 in the Methods. The values for maximal and minimal peak rate of the left ventricular pressure in SHRs were similar between the groups as shown in Figure 6A . In the same animals, the HW and TL ratio was not different between the groups (GFP: 2.9 + 0.08; CBA-MIF: 2.97 + 0.03 mg/mm) (P ¼ 0.394, Figure 6B ). Both SHR groups exhibited significantly greater HW/TL ratios when compared with NT rats [2.3 + 0.1 mg/mm; F(2,15) ¼ 21.19, P , 0.05; Figure 6B ].
Discussion
The major findings of this study are: (i) MIF mRNA levels in the NTS are similar between SHRs and NT rats, but from a qualitative view the cellular distribution of endogenous immunoreactive MIF protein at this nucleus is different between the strains. In NT rats MIF is abundant in neurons, with lesser occurrence in astrocytes. However, in SHR MIF immunoreactivity was present in astrocytes in the NTS, and was not observed in neurons; (ii) an increased expression of MIF within NTS neurons produced a significant reduction in MAP in SHRs but not in NT rats; (iii) This reduction in MAP elicited by MIF in SHRs was associated with a restoration of baroreflex function; (iv) The reduction in MAP elicited by an increased MIF expression in the NTS of SHRs was not associated with changes in cardiac function in these animals. These data raise many questions concerning the contribution and role of MIF in the CNS regulation of blood pressure. Our previous studies led us to conclude that MIF in the PVN serves as an essential negative regulator of the actions of ANG II on sympathetic activity and blood pressure in NT rats, and that this MIF regulatory mechanism is absent or depleted in SHRs, contributing to their hypertension. The current data provide the novel demonstration that the negative regulatory actions of MIF on the modulation of blood pressure are not restricted to the PVN, but also include actions within the NTS. Specifically, in the present study, we demonstrated that MIF over expression in NTS neurons of SHRs was able to lower MAP, and also improve baroreflex function in these animals to the level observed in NT controls. Since it is well known that an ANG II-dependent mechanism in the NTS is responsible for the impairment of a baroreflex control in SHRs, 10, 23 and that SHRs exhibit over activity of the RAS in the brain, 7 it is reasonable to suggest that the improvement of baroreflex function observed following an increased MIF expression in the NTS of SHRs may be due to the inhibition of ANG II's enhanced actions in these rats. Further, these data suggest that MIF expression in the NTS astrocytes and not in neurons may contribute to the reduced baroreflex function observed in SHRs.
Even though an increased expression of MIF in the NTS of SHRs lowered MAP, there was no associated reduction in cardiac hypertrophy or improvement in cardiac function in these rats. This is in contrast to our previous study in which an increased expression of MIF in the PVN of SHRs lowered MAP and reduced cardiac hypertrophy. 19 This discrepancy may be due to multiple factors. For example, the reduction in MAP produced by MIF in the current study was less than that produced by MIF over expression in the PVN. In addition, the previous study was carried out over a longer time course of MIF expression (84 days) vs. 31 days in the current study. It remains to be seen whether longer-term exposure to increased MIF expression in the NTS elicits greater decreases in MAP and also restores cardiac function in SHRs. Despite the fact that MIF restores baroreflex function in SHRs, it is also known that enhanced sympathetic mechanisms at the NTS are a causal factor in hypertension. 4 -6 The NTS is a source for both sympathoinhibition and sympathoexcitation depending upon different projections to ventral regions in the medulla oblongata (reviewed in Colombari et al.
24
). Thus, considering our previous observation that MIF acts at the PVN to reduce the sympathetic outflow, 17 it is possible that the reduction in BP in SHRs following MIF expression in the NTS also involves a reduction in sympathoexcitation.
A further question concerns the mechanism of action of MIF in lowering MAP in SHRs. On the basis of our previous studies, we predicted that this action of MIF was mediated through scavenging of ROS in NTS neurons by the TPOR moiety of MIF. 15 The idea that decreased ROS levels in the NTS could account for the MAP reduction observed in SHRs is certainly plausible. For example, studies demonstrated that a decrease in Rac1-derived ROS in stroke-prone SHRs reduces blood pressure, suggesting that ROS hyperactivity in the NTS is able to maintain the high blood pressure levels in these rats. 25 In addition, a recent study demonstrated that MAP and ROS levels in the NTS (intermediate and commissural regions) of SHRs are reduced after the treatment with losartan or tempol, due to diminished activation of AT1 receptors and/or decreased ROS and increased NO production, that can act as an arterial pressure buffer in the NTS. 20 Recently, it was demonstrated that reduction in superoxide in the PVN can block the development of renovascular hypertension in a mouse model. 26 Several studies have shown that peripheral 27 -29 and central 30 antioxidant administration can decrease the blood pressure in hypertensive rats, implying that in hypertensive models the oxidative stress is essential to maintain high blood pressure. Thus, we suggest that a ROS scavenging action of MIF in the NTS may contribute to the decreases in MAP observed in the current study. Furthermore, it is plausible that antioxidant proteins, including MIF, may represent a potential therapeutic avenue in hypertension that is neurogenic in origin. In summary, even though a number of questions remain, our data provide new evidence for a regulatory action of MIF over baroreflex function at the NTS and suggest that this protein has an important role in the CNS control of cardiovascular function.
